請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43342
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 忻凌偉 | |
dc.contributor.author | Yi-Lin Liu | en |
dc.contributor.author | 劉易霖 | zh_TW |
dc.date.accessioned | 2021-06-15T01:50:44Z | - |
dc.date.available | 2016-08-01 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-15 | |
dc.identifier.citation | Part I:
1. Charrow, J; Esplin, J. A.; Gribble, T. J.; Kaplan, P.; Kolodny, E. H.; Pastores, G. M.; Scott, C. R.; Wappner, R. S.; Weinreb, N. J.; Wisch, J. S. Gaucher Disease. Arch Intern Med. 1998, 158, 1754-1760. 2. McCormack, P. L.; Goa, K. L. Miglustat. Drugs. 2003, 63, 2427-2434. 3. Grabowski, G. A. Gaucher Disease: lessons from a decade of therapy. Journal of Pediatrics. 2004, 144, S15-19. 4. For miglustat (OGT918, Zavesca®) In niemann-pick type C disease. FDA Advisory Briefing Book. 2009, 656, 2-136. 5. Norez, C.; Noel, S.; Wilke, M.; Bijvelds, M.; Jorna, H.; Melin, P.; DeJonge, H.; Becq, F. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Letters. 2006, 580, 2081–2086. 6. Baxter, E. W.; Reitz, A. B. Expeditious Synthesis of azasugars by the double reductive amination of dicarbonyl sugars. J. Org. Chem. 1994, 59, 3175-3185. 7. Reitz, A. Process for producing polyhydroxylated piperidines and pyprolidines and compounds thereof. WO 92/05152 Part II: 1. Li, Z.; Conti, P. S. Radiopharmaceutical chemistry for positron emission tomography. Advanced Drug Delivery Reviews. 2010, 62, 1031-1051. 2. Miller, P. W.; Long, N. J.; Vilar, R.; Gee, A. D. Synthesis of 11 C, 18 F, 15 O, and 13 N radiolabels for positron emission tomography. Angew. Chem. Int. Ed. 2008, 47, 8998-9033. 3. Guillot, T. S.; Miller, G. W. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 2009, 39, 149-170. 4. Zheng, G.; Dwoskin, L. P.; Crooks, P. A. Vesicular monoamine transporter 2: role as a novel target for drug development. The AAPS Journal. 2006, 8, E683-E692. 5. DaSilva, J.N.; Carey, J.E.; Sherman, P.S.; Pisani, T.J.; Kilbourn, M.R. Characterization of [ 11C ]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter. Nucl. Med. Biol. 1994, 21, 151-156. 6. Rishel, M. J.; Amarasinghe, K. K. D.; Dinn, S. R.; Johnson, B. F. Asymmetric synthesis of tetrabenazine and dihydrotetrabenazine. J. Org. Chem. 2009, 74, 4001-4004. 7. Anlauf, M.; Eissele, R.; Schäfer, M. K.; Eiden, L. E. et al.. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J. Histochem. Cytochem. 2003, 51, 1027-1040. 8. Souza, F.; Freeby, M.; Hultman, K. et al. Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas. Curr. Med. Chem. 2006, 13, 2761-2773. 9. Simpson, N. R.; Souza, F.; Witkowski, P. et al. Visualizing pancreaticβ-cell mass with [11C] DTBZ. Nucl. Med. Biol. 2006, 33, 855-864. 10. Goland, R.; Freeby, M.; Parsey, R. et al. 11C-Dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J. Nucl. Med. 2009, 50, 382-389. 11. Caliskan, E.; Cameron, D. W.; Griffiths, P. G. Synthesis of Homophthalates from Allenic Diesters: Conversion into Viocristin and Analogues, and Application to 6-Methylpretetramid. Aust. J. Chem. 1999, 52, 1013-1020. 12. Wiktelius, D.; Larsson, E. K.; Luthman, K. Chemoenzymatic synthesis of enantiomerically enriched alpha-chiral 3-oxy-propionaldehydes by lipase-catalyzed kinetic resolution and desymmetrization. Tetrahedron: Asymmetry. 2006, 17, 2088–2100. 13. Dess, D. B.; Martin, J. C. A useful 12-I-5 triacetoxyperiodinane (the Dess-Martin Periodinane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species. J. Am. Chem. Soc. 1991, 113, 7277-7287. 14. Nicola, T.; Schwarzrock, D.; Keller, M.; Eberbach, W. The synthesis of annulated 4-quinolizinones by two sequential anionic cyclizations. Tetrahedron. 2001, 57, 1771–1777. 15. Yadav, J. S.; Narasimhulu, G.; Reddy, N. M. B.; Reddy, V. S. Total synthesis of (+)-pseudohygroline. Tetrahedron Letters. 2010, 51, 1574–1577. 16. Jung, M. E.; Kaas, S. M. Facile synthesis of a substituted bicyclo[4.2.l]nonane via an anionic [1,3]-sigmatropic shift : use of long range 2D hector and difference noe in structure determination. Tetrahedron Letters. 1989, 30, 641-644. 17. Heydenreich, M.; Koch, A.; Lázár, L.; Szatmári, I.; Sillanpáá, R.; Kleinpeter, E.; Fülöp, F. Synthesis and stereochemical studies of 1- and 2-phenyl-substituted 1,3-oxazino[4,3-a]isoquinoline derivatives. Tetrahedron. 2003, 59, 1951–1959. 18. Lafrance, M.; Blaquiere, N.; Fagnou, K. Aporphine alkaloid synthesis and diversification via direct arylation. Eur. J. Org. Chem. 2007, 811–825. 19. Dondoni, A.; Marra, A.; Massi, A. Design and use of an oxazolidine silyl enol ether as a new homoalanine carbanion equivalent for the synthesis of carbon-lnked isosteres of O-glycosyl serine and N-glycosyl asparagines. J. Org. Chem. 1999, 64, 933-944. 20. Taketoshi, A.; Hosoda, H.; Yamaguchi, Y.; Asami, M. Diastereoselective allylation of 3,4-dihydro-4-phenylisoquinoline. Convenient methods for the preparation of cis- and trans-1-allyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline. Bull. Chem. Soc. Jpn. 2007, 80, 2418–2424. 21. Okamoto, S.; Teng, X.; Fujii, S.; Takayama, Y.; Sato, F. An allyltitanium derived from acrolein 1,2-dicyclohexylethylene acetal and (tao2 -propene)Ti(O-i-Pr)2 as a chiral propionaldehyde homoenolate equivalent that reacts with imines with excellent stereoselectivity. An efficient and practical access to optically active gamma-amino carbonyl compounds. J. Am. Chem. Soc. 2001, 123, 3462-3471. 22. Noyori, R.; Hashiguchi, S. Asymmetric transfer hydrogenation catalyzed by chiral ruthenium complexes. Acc. Chem. Res. 1997, 30, 97-102. 23. Szawkało, J.; Czarnocki, S. J.; Zawadzka, A.; Wojtasiewicz, K.; Leniewski, A.; Maurin, J. K.; Czarnocki, Z.; Drabowicz, J. Enantioselective synthesis of some tetrahydroisoquinoline and tetrahydro-beta-carboline alkaloids. Tetrahedron: Asymmetry. 2007, 18, 406–413. 24. Yu, Q. S.; Luo, W.; Deschamps, J.; Holloway, H. W.; Kopajtic, T.; Katz, J. L.; Brossi, A.; Greig, N. H. Preparation and characterization of tetrabenazine enantiomers against vesicular monoamine transporter 2. ACS Med. Chem. Lett. 2010, 1, 105–109. 25. Ladame, S.; Bardet, M.; Périé, J.; Willson, M. Selective inhibition of trypanosoma brucei GAPDH by 1,3-bisphospho-D-glyceric acid (1,3-diPG) analogues. Bioorganic& medicinal chemistry. 2001, 9, 773-783. 26. Flipo, M.; Beghyn, T.; Charton, J.; Leroux, V. A.; Deprez, B. P. ; Deprez-Poulain, R. F. A library of novel hydroxamic acids targeting the metallo-protease family: Design, parallel synthesis and screening. Bioorganic & Medicinal Chemistry. 2007, 15, 63–76. 27. Ostermeier, M.; Brunner, B.; Korff, C.; Helmchen, G. Highly enantioselective rhodium-catalyzed hydrogenation of 2-(2-Methoxy-2-oxoethyl)acrylic acid - a convenient access of enantiomerically pure isoprenoid building blocks. Eur. J. Org. Chem. 2003, 3453-3459. 28. Ihara, M.; Takahashi, M.; Taniguchi, N.; Yasui, K.; Fukumoto, K. Asymmetric syntheses of chiral propane-I ,3-diols starting from malonic acid. J. Chem. Soc. Perkin Trans. 1989, 1, 897-903. 29. Chandrasekhar, S.; Reddy, Ch. R. Towards a synthesis of epothilone A: asymmetric synthesis of C(1)-C(6) and C(7)-C(15) fragments. Tetrahedron: Asymmetry. 2002, 13, 261–268. 30. Gawinecki, R.; Kolehmainen, E.; Loghmani-Khouzani, H.; Ośmiałowski, B.; Lovász, T.; Rosa, P. Effect of π-electron delocalization on tautomeric equilibria – benzoannulated 2-phenacylpyridines. Eur. J. Org. Chem. 2006, 2817–2824. 31. Wheeler, J. W.; Avery, J.; Olubajo, O.; Shamim, M. T.; Storm, C. B. Isolation, identification and synthesis of 5-methyl-3-n-propyl-2-(1-butenyl) pyrazine from aphaenogaster ants (formicdae). Tetrahedron. 1982, 38, 1939-1948. 32. Onda, M.; Sugama, Y.; Yabuki, R. Methylation of the cyclic enamino ketones. Heterocycles. 1985, 23, 111-116. 33. Meyers, A. I.; Reine, A. H.; Gault, R. The chemistry of cyclic enamino ketones. IV. Factors affecting C and O alkylation. Cyclic Enamino Ketones. 1969, 34, 698-705. 34. Shen, Y.; Burgoyne, D. L. Efficient synthesis of IPL576,092: A novel anti-asthma agent. J. Org. Chem. 2002, 67, 3908-3910. 35. Furth, P. S.; Hwu, J. R. Silicon-directed decarbonylation of trans trimethylsilyl formyl octalins. J. Am. Chem. Soc. 1989, 111, 8842-8849. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43342 | - |
dc.description.abstract | 第一部分:
高雪氏症是一種無法正常提供 glucocerebrosidase而引起醣酯類儲積症的體染色體隱性遺傳疾病。目前 Zavesca® (miglustat) 已經被美國以及歐盟核准用來治療第一型高雪氏症疾病,它是以抑制醣脂合成酶來治療高雪氏症的藥物。然而此藥不易取得,且一名病人的藥品費一年約需四百萬台幣。因此我們探討以較經濟的成本合成原料藥 miglustat 的可行性。在此我們成功的利用1,2-O-isopropylidene-alpha-D-glucofuranose 為起始物經由氧化、水解以及環化等三步反應合成出原料藥 miglustat (總產率為 40%), 同時我們也利用高效能液相層析儀搭配蒸發式光散射偵檢器建立 miglustat 的定量分析方法。我們相信此製程是具有量產 miglustat 的潛力。 第二部分: Tetrabenazine (TBZ) 為一種FDA核准用於治療杭亭頓病之舞蹈症的藥物,此外 (+)-TBZ和 (+)-alpha-DTBZ 是具有高度潛力應用在正子斷層掃描之分子影像試劑。本研究主要探討以不對稱合成製備單一鏡像的 (+)-TBZ。我們使用了丙二酸二甲酯為起始物,經由烷化、還原、選擇性的保護和氧化反應成醛類化合物後,與利用異喹啉衍生物所製備出的 Grignard 試劑進行親核性加成反應。由於加成反應所得到之化合物穩定度不佳,我們探討了一些解決辦法後,模擬出兩個較佳的合成路徑,最後都成功的經由分子內環化得到消旋之 TBZ,且此分子內環化具有良好 diastereomeric selectivity。接著使用 Noyori 催化劑進行不對稱之還原反應,第一種路徑可以成功合成出具有光學活性之 (+)-TBZ。但是另外一種路徑所合成出的中間體因為有較強的共振系統和立體障礙的關係,無法使用此催化劑進行不對稱之還原。同時也利用 chiral-HPLC 偵測反應過程所產生的中間體之光學活性,發現只有在環化的過程中會有消旋現象的產生。本研究成功的開闢以不對稱全合成製備單一鏡像的 (+)-TBZ之方法,未來我們期望進一步的改良此路徑使得可合成出具有更高光學活性之 (+)-TBZ。 | zh_TW |
dc.description.abstract | Part I:
Gaucher’s disease is an autosomal recessive genetic disorde and is caused by abnormal glucocerebrosidase in the patient. Miglustst is a potent glycolipid synthase inhibitor and has been approved in US and EU for the treatment of Type I Gaucher’s disease. However, this drug is not easy to obtain and the expense of the drug cost each patient 4 million NT dollars per year. Therefore, the potentiality of synthesis of the miglustat by economic cost is awaited. In this research, we have succeed in using 1,2-O-isopropylidene-alpha-D-glucofuranose as the start material to synthesize miglustat in three steps such as oxidation, hydrolysis and cyclization (40% overall yield). we also have used high-performance liquid chromatography with evaporative light-scattering detector to establish the quantitative analysis of miglustat. We believed that this process has the potential for the scale up production of miglustat. Part II: TBZ is approved by FDA for the treatment of chorea associated with Huntington’s disease. In addition, positron-emitter labeled (+)-TBZ and (+)-alpha-DTBZ as potent PET imaging agents. This research is to explore the asymmetric total synthesis of (+)-TBZ. First, we used dimethyl malonate as the start material to do alkylation, reduction, selective protection and oxidation to afford the aldehyde compound. Then we used the aldehyde compound to do nucleophilic addition reaction with the Grignard reagent which is prepared by isoquinoline derivative. Unfortunately, the addition compound was not stable. We explored two better methods to solve this problem. Finally, these two methods were succeeded in affording racemate TBZ through intramolecular cyclization and this intramolecular cyclization had good diastereomeric selectivity. Then to use Noyori catalyst to do asymmetric reductive reaction. The results showed that the first of the study can succeed in synthesis of the (+)-TBZ containing optical activity (48% and 62% e.e). The another study cannot do asymmetric reduction by using this catalyst because the intermediate from this study had a stronger resonance system and the relationship of the steric effect. Moreover, to use the chiral-HPLC to detect the optical activity of intermediate in the previous study. The phenomenon of racemization was only detected in cyclization process. To sum up, in this research was succeed developing the method of asymmetric total synthesis of (+)-TBZ. In the future, we will expect to further improve this study to afford the high optical activity of (+)-TBZ. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T01:50:44Z (GMT). No. of bitstreams: 1 ntu-100-R98423013-1.pdf: 5247904 bytes, checksum: 5a35abdddbcdf2f0bfff99416f7376fe (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 目錄
口試委員會審定書 .…………………………………………………I 誌謝 …………………………………………………………………II 中文摘要 ……………………………………………………………III 英文摘要 ……………………………………………………………V 目錄 ………………………………………………………………VII 圖目錄 ………………………………………………………………IX 表目錄 ………………………………………………………………..X 路徑目錄 ………………………………………………………………XI 英文縮寫表 …………………………………………………………XIII 第一部分 .……………………………………………………………1 第一章 緒論 …………………………………………………………2 1.1 背景 ……………………………………………………………2 1.2 研究動機與目的 …… ……………………………………………4 第二章 結果與討論 …………………………………………………5 2.1 Miglustat 原料藥的製程方法 …………………………………6 2.2 Miglustat 成品之分析 …………………………………………7 第三章 結論 …………………………………………………………9 參考文獻 ……………………………………………………………10 第二部分 …………………………………………………………11 第一章 緒論 ……………………………………………………12 1.1 正子斷層掃描 ………………………………………………12 1.2 囊泡單胺轉運體 ……………………………………………13 1.3 第二型囊泡單胺轉運體之臨床研究 ………………………14 1.4 研究動機與目的 ……………………………………………16 第二章 結果與討論 ……………………………………………17 2.1 (+)-TBZ 的逆合成分析 ……………………………………17 2.2 化合物 C 合成之研究 ……………………………………18 2.3 Racemic TBZ 合成之研究 …………………………………21 2.4不對稱合成TBZ 之研究一 …………………………………25 2.5. 分析各化合物之立體位向和光學活性 …………………33 2.6 其他方法之合成路徑 ………………………………………43 2.6.1 化合物 24 合成之研究 …………………………………43 2.6.2 Racemic TBZ 合成之研究二 ……………………………44 2.6.3 不對稱合成 TBZ 之研究二………………………………49 第三章 結論 ……………………………………………………52 參考文獻 …………………………………………………………55 實驗部分 1 實驗藥品及溶劑 1.1 藥品及溶劑 …………………………………………………60 1.2 自製無水溶劑 ………………………………………………62 2 實驗儀器裝置 …………………………………………………62 3 合成步驟與數據分析 …………………………………………64 附圖目錄 …………………………………………………………97 附圖 ……………………………………………………………100 | |
dc.language.iso | zh-TW | |
dc.title | 第一部分 : Miglustat的製程研究
第二部分 : (+)-Alpha-Dihydrotetrabenazine 之不對稱全合成 | zh_TW |
dc.title | Part I : Synthetic Process Study of Miglustat
Part II : Asymmetric Total Synthesis of (+)-Alpha-Dihydrotetrabenazine | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王光昭,陳基旺,薛晴彥,梁碧惠 | |
dc.subject.keyword | 罕見疾病,高雪式症孤兒藥,囊泡單胺轉運體2,不對稱全合成,正子斷層之造影劑, | zh_TW |
dc.subject.keyword | Miglustat,VMAT2,asymmetric total synthesis,PET imaging agent,TBZ, | en |
dc.relation.page | 182 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 5.12 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。